Bupropion (previously known as amfebutamone; Wellbutrin, Zyban) is an atypical antidepressant that acts as a norepinephrine and dopamine reuptake inhibitor, and nicotinic antagonist. Bupropion belongs to the chemical class of aminoketones and is similar in structure to the stimulant cathinone, to the anorectic diethylpropion, and to phenethylamines in general. Initially researched and marketed as an antidepressant, bupropion was subsequently found to be effective as a smoking cessation aid.
Researchers may have pinpointed a reason many smokers struggle to quit. According to new research published in the journal Addiction, smokers with a history of anxiety disorders are less likely to quit smoking. The study, conducted by the University of Wisconsin Center for Tobacco Research and Intervention (UW-CTRI), offered free coaching and medications to smokers in Madison and Milwaukee.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Bupropion Hydrochloride Extended-release Tablets USP, 150 mg, the generic version of GlaxoSmithKline's smoking cessation aid, Zyban.
Recently published research has shown that some breast cancer patients taking tamoxifen may not be getting the full benefit of their treatment because they have also been taking selective serotonin reuptake inhibitors, prescribed drugs that inhibit the effect of an important enzyme.
Recently published research has shown that some breast cancer patients taking tamoxifen may not be getting the full benefit of their treatment because they have also been taking selective serotonin reuptake inhibitors (SSRIs), prescribed drugs that inhibit the effect of an important enzyme. Now researchers have developed a strategy for overcoming this problem, the seventh European Breast Cancer Conference (EBCC7) in Barcelona will hear today (Wednesday).
New research from the University of Pennsylvania School of Medicine may help more smokers keep their New Year's resolution by helping them quit smoking. Extended use of a nicotine patch - 24 weeks versus the standard eight weeks recommended by manufacturers - boosts the number of smokers who maintain their cigarette abstinence and helps more of those who backslide into the habit while wearing the patch, according to a study which will be published in the February 2 issue of Annals of Internal Medicine.
22nd Century Limited, LLC is pleased to announce that it is continuing development of a very low nicotine cigarette for use in smoking cessation. Clinical trial results demonstrate that these cigarettes, also referred to as ‘nicotine-free’ and ‘denicotinized,’ may be more effective for quitting than FDA-approved therapies.
The U.S. Food and Drug Administration has announced that it is requiring manufacturers to put a Boxed Warning on the prescribing information for the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion). The warning will highlight the risk of serious mental health events including changes in behavior, depressed mood, hostility, and suicidal thoughts when taking these drugs.
Tobacco use is more prevalent and smoking cessation less likely among persons with Attention Deficit Hyperactivity Disorder (ADHD).
Scientists have identified distinct clusters of genetic markers associated with the likelihood of success or failure of two smoking cessation treatments, nicotine replacement therapy (NRT) and the medication bupropion (Zyban). This study, supported by the National Institute on Drug Abuse (NIDA) and the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), was published in the June issue of the journal Archives of General Psychiatry.
should you switch to a different medication from the same class or should you try an antidepressant medication that has a different mechanism of action?
A genetic variant present in nearly half of Americans of European ancestry is linked to greater effectiveness of the smoking cessation medication bupropion (Zyban), according to research by scientists supported by the National Institute on Drug Abuse (NIDA) and the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
Quitting smoking is not easy, but thousands of New Yorkers succeed at it every year. Who's trying to kick the habit, and who's succeeding? In a new report titled Who's Still Smoking?, the Health Department sheds light on both questions.
The Food and Drug Administration (FDA) in the United States wants the manufacturers of antidepressant medications to change the labels on their products.
Researchers in the United States say smokers who fail to quit smoking by using pills, should not be disheartened and should try again.
Scientists have found that a new anti-smoking drug may be more effective than drugs currently in use to help smokers kick the habit and it has the added advantage of promoting longer-lasting abstinence.
The U.S. Food and Drug Administration (FDA) has given approval for the sale of the first smoking cessation drug in almost ten years.
Smokers who try to quit using existing medications, such as nicotine patches or Zyban, are about twice as likely to succeed as those who don't use medication or are prescribed placebos during clinical trials.
An editorial in the January 2006 issue of the Psychiatric Bulletin reviews the evidence for the effectiveness of gene-based smoking cessation packages, and asks whether they are appropriate for psychiatric patients.
An experimental smoking cessation drug by Pfizer apparently gives smokers better odds at kicking the habit.
According to new research by the National Health Service (NHS), 60 per cent of smokers light up and smoke without asking for permission, despite the fact that most non-smokers mind if other people are smoking nearby.